5 studies found for:    gdc-0973 | Open Studies | Exclude Unknown
Show Display Options
Rank Status Study
1 Recruiting Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Conditions: Melanoma;   Metastatic Melanoma
Interventions: Drug: Vemurafenib;   Drug: Bevacizumab;   Drug: Cobimetinib
2 Recruiting A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors
Condition: Neoplasms
Interventions: Drug: Cobimetinib;   Drug: MPDL3280A
3 Recruiting A Study of MEHD7945A and Cobimetinib (GDC-0973) in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS
Condition: Neoplasms
Interventions: Drug: MEHD7945A;   Drug: cobimetinib
4 Not yet recruiting Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Condition: Active Melanoma Brain Metastases
Interventions: Drug: Cobimetinib;   Drug: Vemurafenib
5 Recruiting A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer
Conditions: Advanced Adenocarcinoma;   Metastatic Adenocarcinoma
Interventions: Drug: Hydroxychloroquine (HCQ);   Drug: Gemcitabine

Indicates status has not been verified in more than two years